HR-positive, HER2-negative advanced or metastatic breast cancer in combination with:
Aromatase inhibitors
Fulvestrant
Key Features
Potent and selective CDK4/6 inhibition
Established overall survival benefit in HR+/HER2- advanced breast cancer
Oral, once-daily administration
Well-documented safety and clinical data
Applications
API, intermediates, reference standards for R&D, generic registration and commercial manufacturing.
Short English Sales Copy (LinkedIn / Email)
Ribociclib (CAS 1211441-98-3)Highly selective oral CDK4/6 inhibitor for HR+/HER2- advanced breast cancer.We supply high-purity Ribociclib API & intermediates for global pharmaceutical R&D and production.
ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea